Latest Breaking News On - Professor leihong xiang - Page 1 : comparemela.com

Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces initiation of the Phase III clinical trial of fatty acid synthase (FASN).

Hong kongAnn pharmacotherLeihong xiangJinzij wuSagimet biosciences incNational medical products administrationInstitute of dermatologyFudan universityAscletis pharma incPhysician of dermatological departmentDermatology division of chinese medical doctor associationHong kong stock exchangePrnewswire ascletis pharma incDrug evaluationInstitutional review boardHuashan hospital

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongJinzij wuLeihong xiangSagimet biosciences incAscletis pharma incFudan universityEuropean academy of dermatologyHong kong stock exchangeAscletis pharmaEuropean academyProfessor leihong xiangHuashan hospitalGlobal assessmentSagimet biosciences

Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China

Suzhou, October 16, 2022 - Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the. | October 16, 2022

Leihong xiangKintor pharmaFudan universityKintor pharmaceutical limited pharmaPharmaceutical limitedInvestigator global assessmentYouzhi tongChief executive officerProfessor leihong xiangHuashan hospitalKintor pharmaceutical limited stock exchangePress releaseHat 9939 kyg5273b1077

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China

/PRNewswire/ Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and.

Leihong xiangKintor pharmaFudan universityPrnewswire kintor pharmaceutical limited pharmaPharmaceutical limitedInvestigator global assessmentYouzhi tongChief executive officerProfessor leihong xiangHuashan hospitalKintor pharmaceuticals